Jennifer Chu

Jennifer L. Chu is a corporate partner and member of the firm’s Mergers & Acquisitions and Private Equity Groups. Her practice focuses on advising corporations and private equity firms in mergers and acquisitions, joint ventures and other corporate matters, across a broad range of industries with a particular focus on transactions in the healthcare, financial services and insurance industries.

Ms. Chu is recognized as a “Next Generation Lawyer” by The Legal 500 US (2018), where she is described as “very seasoned in handling private equity matters.” She co-led The Deal’s “Private Equity Deal of the Year” (2018) for representing TPG Capital and Welsh, Carson, Anderson & Stowe, with Humana, in their $4.1 billion acquisition of Kindred Healthcare.

Ms. Chu was named to Crain’s New York Business’s 2019 list of “Notable Women in Law” and selected as a 2017 “Rising Star” by the New York Law Journal.

Ms. Chu publishes and speaks regularly on M&A and private equity matters. She is a contributing author to the annual Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2018), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues in healthcare M&A and licensing transactions.

Her articles include: co-author of “How Tax Reform Could Impact the Healthcare Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Shining a Light on GOP Plan for Health Care Reform,” Law360 (March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook on Drug Pricing: At What Cost?,” Law360 (December, 2016) and “A Closer Look: Increased Cybersecurity Regulations are Impacting the Insurance and Financial Technology Sectors,” Best’s Review (June, 2015). She is an editor of The Debevoise & Plimpton Private Equity Report.

Ms. Chu’s recent ‎speaking engagements include “Indemnification Issues,” Acquiring and Selling the Privately Held Company 2018 (June, 2018) and “Health Care M&A: Three Hot Topics,” PLI One-Hour Briefing (April, 2017).

Ms. Chu is actively involved in the development of young lawyers, particularly women and diverse lawyers. She co-chairs Debevoise’s Women’s Resource Group and is a member of its Diversity Committee. She serves on the Board of Directors of Practicing Attorneys for Law Students, a not-for-profit organization focusing on enhancing the skills and careers of minority law students and early career lawyers through mentoring, education and professional development opportunities.

She has spoken on panels about women in the legal profession, including at the Annual Conference of the National Association of Women Lawyers and at Harvard Law School. She is also a 2015 Alumni of the Fellows Program of the Leadership Council on Legal Diversity, an organization of leading corporate chief legal officers and law firm managing partners.

Ms. Chu joined the firm in 2006. She received her J.D. cum laude from Harvard Law School in 2006, where she served as co-editor-in-chief of the Harvard International Law Journal. She received her M.A. with distinction from the University of London in 2002, and her A.B. magna cum laude from Harvard College in 2001.

Ms. Chu is a member of the Bar of New York.

Experience:

• KeyBank in its acquisition of Laurel Road’s affinity-focused digital lending business.
• HCA Healthcare in its $1.5 billion acquisition of Mission Health, a nonprofit North Carolina health system.
• Johnson & Johnson in its acquisition of Zarbee’s Naturals, a leader in naturally-based healthcare products.
• Johnson & Johnson in its sale of Nizoral’s EMEA rights to STADA Arzeimittel AG; LATAM rights to Kramer Laboratories; and APAC rights to Alliance Pharmaceuticals Limited.
• TPG Capital and Welsh, Carson, Anderson & Stowe, with Humana, in their $1.4 billion acquisition of Curo Health Services.
• The Carlyle Group in its strategic minority investment in DiscoverOrg, the leading global sales and marketing intelligence platform.
• TPG Capital and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
• CVC Capital Partners in its investment in Republic Finance, a consumer loan provider.
• Mitsui in its acquisition of an additional 10% limited partnership interest in Penske Truck Leasing from subsidiaries of GE Capital Global Holdings.
• The CF Corporation and The Blackstone Group in the $1.835 billion acquisition of Fidelity & Guaranty Life.
• Allergan in its $2.47 billion acquisition of ZELTIQ, a medical technology company focused on utilizing its proprietary CoolSculpting controlled-cooling technology platform, the sales leader in the fast-growing body contouring segment of medical aesthetics.
• Johnson & Johnson in its purchase of an exclusive option to acquire Bird Rock Bio, a clinical stage biopharmaceutical company focused on innovative immuno-inflammatory regulators that can be used in the treatment of liver disease.
• Allergan in its $2.9 billion acquisition of LifeCell Corporation, a regenerative medicine business.
• Allergan in its global collaboration agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic.
• Lannett in its acquisition for $1.23 billion in cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals, the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB.
• Apollo Global Management in its acquisition of a majority interest in the asset management business of AR Capital (subsequently withdrawn), its acquisition of the wholesale distribution business of RCS Capital and its substantial minority equity investment in RCS Capital.
• Stone Point Capital in its investment in Millstein & Co., a diversified financial services firm that specializes in developing and implementing solutions for complex corporate and public finance problems.
• Actavis in the sale of Aptalis Pharmaceutical Technologies, a pharmaceutical outsourcing and R&D business in the U.S., to TPG.
• Actavis in the sale of its branded respiratory business in the U.S. and Canada to AstraZeneca for $600 million, and an additional payment of $100 million in connection with certain other agreements.
• New York Life Investments in its acquisition of IndexIQ, a leader in the liquid alternative exchange-traded fund industry.
• Blackstone Group’s Tactical Opportunities Group in the acquisition of Philadelphia Financial Group from Tiptree Financial.
• Chemtura in the $1 billion sale of its agrochemicals business, Chemtura AgroSolutions.
• Johnson & Johnson in the sale of its worldwide intimate health business to Reckitt Benckiser, a UK-based consumer goods company.
• PSAV, a Kelso & Company portfolio company, in its acquisition by affiliates of Goldman Sachs.
• Warner Music Group in its $765 million acquisition of the Parlophone Label Group (PLG) from Universal Music Group. (the sale of PLG was required by the European Commission as a condition to its approval of Universal acquiring sole control of the activities of EMI).
• The Special Committee of the Board of Directors of Dell in the $24.9 billion sale of Dell to an investor group including Michael Dell and Silver Lake.
• Goldman Sachs Reinsurance Group in its acquisition of the Bermuda-based reinsurance operations of Ariel Holdings.
• Clayton, Dubilier & Rice in its acquisition of a 60% stake in Hussmann International, a leading global manufacturer of refrigerated display merchandizing equipment and refrigeration systems.

Education:

• Harvard Law School, 2006, J.D.
• University of London, 2002, M.A.
• Harvard University, 2001, A.B.

Bar Admissions:

• New York